|
NZ221411A
(en)
|
1986-08-11 |
1989-10-27 |
Innovata Biomed Ltd |
Pharmaceutical compositions containing microcapsules and a surfactant
|
|
US5179079A
(en)
|
1986-12-16 |
1993-01-12 |
Novo Nordisk A/S |
Nasal formulation and intranasal administration therewith
|
|
GB8723846D0
(en)
|
1987-10-10 |
1987-11-11 |
Danbiosyst Ltd |
Bioadhesive microsphere drug delivery system
|
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
|
FI913899A7
(fi)
|
1989-02-23 |
1991-08-19 |
Rorer Int Holdings Inc |
Terapeuttiset aerosoliseokset
|
|
GB8921222D0
(en)
|
1989-09-20 |
1989-11-08 |
Riker Laboratories Inc |
Medicinal aerosol formulations
|
|
US5731144A
(en)
|
1990-06-11 |
1998-03-24 |
Nexstar Pharmaceuticals, Inc. |
High affinity TGFβ nucleic acid ligands
|
|
US5731424A
(en)
|
1990-06-11 |
1998-03-24 |
Nexstar Pharmaceuticals, Inc. |
High affinity TGFβ nucleic acid ligands and inhibitors
|
|
US5292499A
(en)
|
1990-09-11 |
1994-03-08 |
University Of Wales College Of Cardiff |
Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
|
|
US5230884A
(en)
|
1990-09-11 |
1993-07-27 |
University Of Wales College Of Cardiff |
Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
|
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
|
CH689139A5
(de)
|
1995-04-03 |
1998-10-30 |
Cerbios Pharma Sa |
Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
|
|
US6309671B1
(en)
|
1995-04-14 |
2001-10-30 |
Inhale Therapeutic Systems |
Stable glassy state powder formulations
|
|
US5635161A
(en)
|
1995-06-07 |
1997-06-03 |
Abbott Laboratories |
Aerosol drug formulations containing vegetable oils
|
|
US6120794A
(en)
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
|
JPH10508322A
(ja)
|
1995-10-12 |
1998-08-18 |
スーパーゲン，インコーポレイティド |
５βステロイドのリポソーム配合物
|
|
US6806358B1
(en)
|
1997-12-16 |
2004-10-19 |
University Of California San Diego |
Peptide inhibitor of TGF-β growth factors
|
|
US6943191B1
(en)
|
1998-02-27 |
2005-09-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs
|
|
GB9809869D0
(en)
|
1998-05-09 |
1998-07-08 |
Medical Res Council |
Inhibition of protein kinases
|
|
SK17422000A3
(sk)
|
1998-05-20 |
2001-09-11 |
The Liposome Company, Inc. |
Kompozöcie ¬astöc
|
|
GB9814172D0
(en)
|
1998-06-30 |
1998-08-26 |
Andaris Ltd |
Formulation for inhalation
|
|
US6451349B1
(en)
|
1998-08-19 |
2002-09-17 |
Quadrant Healthcare (Uk) Limited |
Spray-drying process for the preparation of microparticles
|
|
AUPP494798A0
(en)
|
1998-07-29 |
1998-08-20 |
Pacific Biolink Pty Limited |
Protective protein formulation
|
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
US6290987B1
(en)
|
1998-09-27 |
2001-09-18 |
Generex Pharmaceuticals, Inc. |
Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
|
|
ES2146552B1
(es)
|
1998-11-24 |
2001-04-16 |
Inst Cientifico Tecnol Navarra |
Peptidos inhibidores de tgf/31
|
|
US6436367B1
(en)
|
1998-12-21 |
2002-08-20 |
Generex Pharmaceuticals Inc. |
Aerosol formulations for buccal and pulmonary application
|
|
EP1338272A1
(en)
|
1998-12-21 |
2003-08-27 |
Generex Pharmaceuticals Inc. |
Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
|
|
US6294153B1
(en)
|
1998-12-21 |
2001-09-25 |
Generex Pharmaceuticals, Inc. |
Aerosol pharmaceutical formulation for pulmonary and nasal delivery
|
|
WO2000047203A1
(en)
|
1999-02-12 |
2000-08-17 |
Mqs, Inc. |
Formulation and system for intra-oral delivery of pharmaceutical agents
|
|
JP2002542183A
(ja)
|
1999-04-16 |
2002-12-10 |
ノボ ノルディスク アクティーゼルスカブ |
成形可能な乾燥した医薬製剤
|
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
|
US6485706B1
(en)
|
1999-06-04 |
2002-11-26 |
Delrx Pharmaceutical Corp. |
Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
|
|
US20010036481A1
(en)
|
1999-08-25 |
2001-11-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
|
EP1210067A2
(en)
|
1999-08-25 |
2002-06-05 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
|
ATE267582T1
(de)
|
2000-01-20 |
2004-06-15 |
Basilea Pharmaceutica Ag |
Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen
|
|
EP1129705A1
(en)
|
2000-02-17 |
2001-09-05 |
Rijksuniversiteit te Groningen |
Powder formulation for inhalation
|
|
GB0009468D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
|
CA2406206C
(en)
|
2000-04-17 |
2012-03-20 |
Vectura Limited |
Improvements in or relating to formulations for use in inhaler devices
|
|
US20020155084A1
(en)
|
2000-06-02 |
2002-10-24 |
The Regents Of The University Of The Michigan |
Nanoemulsion formulations
|
|
US6509318B1
(en)
|
2000-09-29 |
2003-01-21 |
The Regents Of The University Of California |
TGF-B inhibitors and methods
|
|
FI20002768L
(fi)
|
2000-12-18 |
2002-06-19 |
Licentia Oy |
Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
|
|
US20030134836A1
(en)
*
|
2001-01-12 |
2003-07-17 |
Amgen Inc. |
Substituted arylamine derivatives and methods of use
|
|
GB0107106D0
(en)
|
2001-03-21 |
2001-05-09 |
Boehringer Ingelheim Pharma |
Powder inhaler formulations
|
|
SK287857B6
(sk)
|
2001-05-24 |
2012-01-04 |
Eli Lilly And Company |
Novel pyrrole derivatives as pharmaceutical agents
|
|
US20030019437A1
(en)
|
2001-07-26 |
2003-01-30 |
John Fore |
Ungulate game animal feed system and method
|
|
US20030028905A1
(en)
|
2001-07-31 |
2003-02-06 |
Petra Knaus |
Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
|
|
US20030064033A1
(en)
|
2001-08-16 |
2003-04-03 |
Brown Larry R. |
Propellant-based microparticle formulations
|
|
AU2003215334A1
(en)
|
2002-02-22 |
2003-09-09 |
Advanced Inhalation Research, Inc. |
Inhalable formulations for sustained release
|
|
WO2003079885A2
(en)
|
2002-03-20 |
2003-10-02 |
Advanced Inhalation Research, Inc. |
Inhalable sustained therapeutic formulations
|
|
HRP20041152B1
(hr)
|
2002-05-07 |
2008-01-31 |
Ferring B.V. |
Farmaceutske formulacije
|
|
EP1506191A1
(en)
|
2002-05-15 |
2005-02-16 |
Smithkline Beecham Corporation |
Benzoxazine and benzoxazinone substituted triazoles
|
|
AU2003229305A1
(en)
|
2002-05-17 |
2003-12-02 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
|
|
US7190468B2
(en)
|
2002-07-17 |
2007-03-13 |
Hewlett-Packard Development Company, L.P. |
Background document rendering system and method
|
|
EP1539748A1
(en)
|
2002-07-31 |
2005-06-15 |
Smithkline Beecham Corporation |
2-phenylpyridin-4-yl derivatives as alk5 inhibitors
|
|
UA80296C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
|
EP1543001B1
(en)
|
2002-09-17 |
2007-08-15 |
Eli Lilly And Company |
Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
|
|
CA2497971A1
(en)
|
2002-09-18 |
2004-04-01 |
Pfizer Products Inc. |
Triazole derivatives as transforming growth factor (tgf) inhibitors
|
|
EP1542995A1
(en)
|
2002-09-18 |
2005-06-22 |
Pfizer Products Inc. |
Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
|
|
WO2004047818A2
(en)
|
2002-11-22 |
2004-06-10 |
Scios, Inc. |
USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
|
|
US8030336B2
(en)
*
|
2002-12-13 |
2011-10-04 |
Ym Biosciences Australia Pty Ltd |
Nicotinamide-based kinase inhibitors
|
|
BRPI0407055A
(pt)
|
2003-01-27 |
2006-01-17 |
Pfizer Prod Inc |
Derivados de isotiazol
|
|
DE602004014347D1
(de)
|
2003-03-12 |
2008-07-24 |
Millennium Pharm Inc |
Chinazolin-derivate als tgf-beta-inhibitoren
|
|
US7223766B2
(en)
|
2003-03-28 |
2007-05-29 |
Scios, Inc. |
Bi-cyclic pyrimidine inhibitors of TGFβ
|
|
ES2389258T3
(es)
|
2003-06-17 |
2012-10-24 |
Millennium Pharmaceuticals, Inc. |
Composiciones y métodos para inhibir TGF-s
|
|
WO2005003101A2
(en)
*
|
2003-07-02 |
2005-01-13 |
Biofocus Discovery Limited |
Pyrazine and pyridine derivatives as rho kinase inhibitors
|
|
WO2005039570A1
(ja)
|
2003-10-28 |
2005-05-06 |
Riken |
ＴＧＦ－β情報伝達経路阻害剤
|
|
MXPA06008157A
(es)
|
2003-12-24 |
2007-09-07 |
Johnson & Johnson |
Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
|
|
EP1723146A1
(en)
|
2004-03-01 |
2006-11-22 |
Eli Lilly And Company |
Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
|
|
WO2006010637A2
(en)
*
|
2004-07-30 |
2006-02-02 |
Gpc Biotech Ag |
Pyridinylamines
|
|
JP2007176795A
(ja)
|
2004-08-18 |
2007-07-12 |
Univ Nihon |
ＴＧＦ−β遺伝子発現抑制剤
|
|
CN101189234B
(zh)
|
2005-03-25 |
2011-08-17 |
泰博特克药品有限公司 |
Hcv的杂二环抑制剂
|
|
PT1910370E
(pt)
|
2005-07-22 |
2015-06-30 |
Lilly Co Eli |
Um pirrolo[1,2-b]pirazole mono-hidratado substituído com piridina e quinolina como inibidor do tgf-beta
|
|
EP1974740A4
(en)
|
2005-10-24 |
2010-09-01 |
Proyecto Biomedicina Cima Sl |
USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT
|
|
WO2007084667A2
(en)
*
|
2006-01-19 |
2007-07-26 |
Osi Pharmaceutical, Inc. |
Fused heterobicyclic kinase inhibitors
|
|
ITMI20060181A1
(it)
|
2006-02-03 |
2007-08-04 |
Univ Padova |
Modulatori del tgf-b e loro uso
|
|
BRPI0807961A2
(pt)
*
|
2007-02-13 |
2017-05-16 |
Pharmacopeia Llc |
agonista de alfa2c adrenorreceptor funcionalmente seletivos.
|
|
WO2009032667A1
(en)
|
2007-08-29 |
2009-03-12 |
Smithkline Beecham Corporation |
Thiazole and oxazole kinase inhibitors
|
|
US8298825B1
(en)
|
2008-08-25 |
2012-10-30 |
The General Hospital Corporation |
TGF-beta receptor inhibitors to enhance direct reprogramming
|
|
MX2011012202A
(es)
*
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Derivados de 5-piridin-3-il-1,3-dihidro-indol-2-ona y su uso como moduladores de a sintanasa de aldosterona y/o de cyp11b1.
|
|
US9216173B2
(en)
*
|
2011-10-05 |
2015-12-22 |
Merck Sharp & Dohme Corp. |
2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
|
|
US9988606B2
(en)
|
2012-07-24 |
2018-06-05 |
The Trustees Of Columbia University In The City Of New York |
Generation of airway and lung progenitors and epithelial cells and three-dimensional anterior foregut spheres
|
|
US20150297573A1
(en)
*
|
2012-10-24 |
2015-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
|
|
HK1213544A1
(zh)
*
|
2012-12-10 |
2016-07-08 |
霍夫曼-拉罗奇有限公司 |
新型二环苯基-吡啶/吡嗪用於治疗癌症
|
|
CA2854542A1
(en)
*
|
2013-06-18 |
2014-12-18 |
4Sc Discovery Gmbh |
Method of inhibiting dyrk1b
|
|
WO2014203217A1
(en)
*
|
2013-06-21 |
2014-12-24 |
Lupin Limited |
Substituted heterocyclic compounds as crac modulators
|
|
US20170280720A1
(en)
*
|
2014-09-17 |
2017-10-05 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
DE112016002687T5
(de)
|
2015-07-11 |
2018-03-01 |
Changzhou Create Electric Appliance Co., Ltd. |
Gleichstrom-Vertikutierer
|
|
EP3328404A4
(en)
*
|
2015-07-27 |
2018-12-26 |
The Regents of The University of California |
Methods and compositions for producing pancreatic beta cells
|
|
US10730842B2
(en)
*
|
2015-09-03 |
2020-08-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Small molecule inhibitors of DYRK1A and uses thereof
|
|
WO2017106630A1
(en)
*
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
US10487087B2
(en)
|
2015-12-30 |
2019-11-26 |
Vanderbilt University |
Positive allosteric modulators of the GLP-1 receptor
|
|
JP6596390B2
(ja)
|
2016-06-29 |
2019-10-23 |
株式会社沖データ |
現像剤収容器、現像装置、画像形成装置、及び基板支持構造
|